Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
A Colton-supported NYU study published in Science Translational Medicine has identified impaired regulatory T cells as a key driver of Sjögren's disease — and found a promising existing drug as a potential therapy.
Yale's Colton Center for Autoimmunity has selected eleven faculty-led projects for 2024 funding, supporting breakthrough research into lupus, asthma, allergies, and other autoimmune diseases — with mentorship and commercialization support included.
